Every 8-K that INTL STEM CELL CORP (ISCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ISCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISCO filings page.
International Stem Cell Corporation (ISCO) completed the sale of 100% of the membership interests of its wholly owned subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. on September 1, 2026 for an adjusted purchase price of $25.688 million, including a fixed cash add‑back and a preliminary working capital adjustment. After estimated transaction costs of $1.027 million and $2.6 million placed in escrow, ISCO received $21.688 million of cash at closing and recorded a current escrow receivable of $2.6 million.
On a pro forma basis as of June 30, 2026, cash and cash equivalents increase to $22.777 million, accumulated deficit is reduced by an estimated after‑tax gain of $21.916 million, and total stockholders’ equity shifts from a deficit of $(4.228) million to positive equity of $17.688 million. Pro forma revenues from continuing operations are significantly lower, at $296,000 for the six months ended June 30, 2026 versus historical revenues of $4.99 million, and the pro forma net loss from continuing operations for that period widens to $1.616 million.
International Stem Cell Corporation agreed to sell 100% of the membership interests of its subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. under a Membership Interest Purchase Agreement signed July 10, 2026. The aggregate purchase price is $25.0 million, subject to closing-date adjustments for net working capital, cash and indebtedness. Cash paid at closing will be reduced by an escrow totaling $2.6 million, comprised of a $100,000 adjustment escrow and a $2.5 million indemnity escrow.
The transaction includes a post-closing adjustment process: the purchaser delivers a closing statement within 90 days after closing, the seller may dispute it within 30 days, and unresolved items go to an independent financial firm. Closing is expected in the third fiscal quarter of 2026, subject to customary conditions and absence of blocking governmental actions.
Stockholders holding more than 50% of the seller’s voting power entered support agreements to approve the deal, grant irrevocable proxies, and restrict transfers, with written stockholder consent required within 24 hours of signing. The agreement imposes covenants on operating LCT in the ordinary course pre-closing, plus five-year post-closing non-solicitation, non-interference and non-compete restrictions, and provides for termination if not closed within 60 days, subject to a limited SEC-related extension.
International Stem Cell Corporation reported voting results from its Annual Meeting of Stockholders held on June 11, 2026. Stockholders voted on the election of directors described in the proxy dated April 24, 2026.
All named director candidates, including Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier, were elected. Support was strong, with 2,457,143 votes "for" Semechkin and Kern, and over 9.28 million votes "for" Wright and Maier against relatively small withheld votes. The company reported no broker non-votes in this election.
International Stem Cell Corporation reported the results of its annual stockholder meeting held on June 17, 2025. Stockholders elected four directors to serve until the 2026 annual meeting, including Andrey Semechkin and Russell Kern, each receiving 2,457,143 votes for with no votes withheld, and Donald A. Wright and Paul V. Maier, each receiving 7,772,429 votes for and 19,267 votes withheld. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 7,715,844 votes for, 73,393 against, and 2,459 abstentions. In addition, stockholders advised that future votes on executive compensation should be held every three years, with 7,593,833 votes favoring a three-year frequency, compared with 142,581 for one year and 50,443 for two years.
International Stem Cell Corporation reported that it has amended a loan agreement with its Co-Chairman and Chief Executive Officer, Dr. Andrey Semechkin. The company and Dr. Semechkin agreed to extend the maturity date of a $2,500,000 loan, originally documented in a promissory note dated September 15, 2024, so that the loan is now due on September 15, 2026 instead of the prior 2025 maturity.
The outstanding principal under the note continues to accrue interest at an annual rate of 5.5%, and the company may prepay the note at any time without penalty. The amended note was issued on September 15, 2025, and a form of the note is included as Exhibit 10.1, providing the detailed terms of this insider financing arrangement.